AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Working Capital to Net Assets Ratio
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Working Capital to Net Assets ratio of 680.4% as of December 2025. Working capital of €-294.15 Million (current assets of €134.40 Million minus current liabilities of €428.55 Million) is measured against net assets of €-43.23 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See AEST.MED.INT.HLD.SP.ADR/3 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
AEST.MED.INT.HLD.SP.ADR/3 Working Capital to Net Assets (2021–2025)
This chart shows how AEST.MED.INT.HLD.SP.ADR/3's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 680.4%, reflecting working capital of €-294.15 Million against net assets of €-43.23 Million EUR. For the complete balance sheet picture, see 3FMA total assets.
Annual Working Capital to Net Assets for AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Explore 3FMA long-term investment intensity to see how much of total assets are deployed in long-term investments.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 680.4% | €-294.15 Million | €-43.23 Million | €134.40 Million | €428.55 Million | ▲ +4039.6 pp |
| 2024 | -3359.3% | €-313.96 Million | €9.35 Million | €88.08 Million | €402.04 Million | ▼ -2467.7 pp |
| 2023 | -891.5% | €-299.81 Million | €33.63 Million | €111.57 Million | €411.38 Million | ▼ -1261.9 pp |
| 2022 | 370.4% | €-466.24 Million | €-125.88 Million | €77.60 Million | €543.84 Million | ▲ +140.8 pp |
| 2021 | 229.6% | €-427.95 Million | €-186.42 Million | €113.71 Million | €541.66 Million | — |